Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 Oct;23(10):e250048.
doi: 10.6004/jnccn.2025.0048.

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025

Andrew D Zelenetz  1 , Leo I Gordon  2 , Jeremy S Abramson  3 , Ranjana H Advani  4 , Babis Andreadis  5 , Nancy L Bartlett  6 , L Elizabeth Budde  7 , Paolo F Caimi  8 , Julie E Chang  9 , Beth Christian  10 , Sven DeVos  11 , Bhagirathbhai Dholaria  12 , Luis E Fayad  13 , Thomas M Habermann  14 , Muhammad Saad Hamid  15 , Francisco Hernandez-Ilizaliturri  16 , Boyu Hu  17 , Yasmin Karimi  18 , Christopher R Kelsey  19 , Rebecca King  14 , Justin Kline  20 , Susan Krivacic  21 , Ann S LaCasce  22 , Daniel Landsburg  23 , Megan Lim  1 , Marcus Messmer  24 , Rachel Rabinovitch  25 , Praveen Ramakrishnan  26 , Erin Reid  27 , Kenneth B Roberts  28 , Hayder Saeed  29 , Naoyuki G Saito  30 , Stephen D Smith  31 , Lode J Swinnen  32 , Joseph Tuscano  33 , Julie M Vose  34 , Mary Dwyer  35 , Hema Sundar  35
Affiliations
Practice Guideline

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025

Andrew D Zelenetz et al. J Natl Compr Canc Netw. 2025 Oct.

Abstract

The treatment landscape of B-cell lymphomas has significantly evolved in recent years with approval of novel targeted therapies. CD3 × CD20 bispecific antibodies and CD19-directed monoclonal antibodies and antibody-drug conjugates have demonstrated efficacy in relapsed/refractory follicular lymphoma (FL). Bruton tyrosine kinase (BTK) inhibitor-based regimens are emerging as effective treatment options for patients with TP53-mutated classical mantle cell lymphoma (MCL). Results from ongoing clinical trials suggest that the addition of CD3 × CD20 bispecific antibodies to chemoimmunotherapy improves outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, MCL, and DLBCL.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources